Pharmarise Holdings Corp.(JP:2796)
Â¥508.000.00 (0.00%)
JP:2796
Pharmarise Holdings Corp. financials statements
Â¥508.00
At close:0.00 (0.00%)
Want to see JP:2796 full AI Analyst Report?
Pharmarise Holdings Corp. (2796) Ratios
0 Followers
Pharmarise Holdings Corp. Ratios
JP:2796's free cash flow for Q1 2026 was ¥0.00. For the 2026 fiscal year, JP:2796's free cash flow was increased by ¥0.00 and operating cash flow was ¥0.00. See a summary of the company’s cash flow.
| Ratios | May 25 | May 24 | May 23 | May 22 | May 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.94 | 1.10 | 1.29 | 1.16 | 1.28 |
| Quick Ratio | 0.74 | 0.76 | 1.04 | 0.92 | 1.01 |
| Cash Ratio | 0.43 | 0.41 | 0.67 | 0.48 | 0.47 |
| Solvency Ratio | 0.07 | 0.04 | 0.04 | 0.09 | 0.10 |
| Operating Cash Flow Ratio | 0.23 | 0.11 | 0.25 | 0.26 | 0.08 |
| Short-Term Operating Cash Flow Coverage | 0.69 | 0.50 | 1.02 | 0.72 | 0.31 |
| Net Current Asset Value | ¥ -12.65B | ¥ -11.83B | ¥ -8.31B | ¥ -5.06B | ¥ -6.17B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.46 | 0.45 | 0.43 | 0.39 | 0.42 |
| Debt-to-Equity Ratio | 2.21 | 2.08 | 1.73 | 1.33 | 1.50 |
| Debt-to-Capital Ratio | 0.69 | 0.68 | 0.63 | 0.57 | 0.60 |
| Long-Term Debt-to-Capital Ratio | 0.59 | 0.62 | 0.57 | 0.43 | 0.52 |
| Financial Leverage Ratio | 4.78 | 4.66 | 4.01 | 3.40 | 3.59 |
| Debt Service Coverage Ratio | 0.39 | 0.46 | 0.33 | 0.46 | 0.78 |
| Interest Coverage Ratio | 3.44 | 1.66 | 13.88 | 26.15 | 23.38 |
| Debt to Market Cap | 2.52 | 2.49 | 1.81 | 1.52 | 1.38 |
| Interest Debt Per Share | 1347.60 | 1276.94 | 1217.69 | 977.92 | 1069.19 |
| Net Debt to EBITDA | 3.54 | 5.59 | 4.06 | 1.89 | 2.20 |
| Profitability Margins | |||||
| Gross Profit Margin | 12.42% | 12.92% | 15.51% | 15.63% | 15.73% |
| EBIT Margin | 1.41% | 0.29% | 0.38% | 2.12% | 2.69% |
| EBITDA Margin | 3.72% | 2.64% | 2.53% | 4.47% | 5.22% |
| Operating Profit Margin | 1.41% | 0.46% | 1.68% | 2.76% | 2.95% |
| Pretax Profit Margin | 1.00% | 0.01% | 0.26% | 2.02% | 2.56% |
| Net Profit Margin | 0.16% | -0.58% | -0.64% | 0.64% | 0.87% |
| Continuous Operations Profit Margin | 0.15% | -0.60% | -0.63% | 0.67% | 0.89% |
| Net Income Per EBT | 16.19% | -4600.00% | -245.45% | 31.74% | 33.81% |
| EBT Per EBIT | 71.22% | 2.71% | 15.61% | 72.95% | 86.97% |
| Return on Assets (ROA) | 0.35% | -1.15% | -1.19% | 1.42% | 1.88% |
| Return on Equity (ROE) | 1.65% | -5.36% | -4.77% | 4.84% | 6.77% |
| Return on Capital Employed (ROCE) | 5.25% | 1.47% | 4.87% | 10.58% | 9.95% |
| Return on Invested Capital (ROIC) | 0.64% | -61.78% | -10.13% | 2.76% | 2.97% |
| Return on Tangible Assets | 0.45% | -1.49% | -1.52% | 1.65% | 2.22% |
| Earnings Yield | 1.95% | -6.70% | -5.17% | 5.80% | 6.58% |
| Efficiency Ratios | |||||
| Receivables Turnover | 18.56 | 16.77 | 15.32 | 12.93 | 12.09 |
| Payables Turnover | 9.19 | 8.32 | 8.09 | 10.32 | 10.58 |
| Inventory Turnover | 21.65 | 13.34 | 17.40 | 19.17 | 18.89 |
| Fixed Asset Turnover | 9.12 | 8.81 | 8.79 | 8.66 | 8.12 |
| Asset Turnover | 2.13 | 1.99 | 1.85 | 2.22 | 2.17 |
| Working Capital Turnover Ratio | 343.27 | 29.54 | 23.75 | 26.42 | 29.03 |
| Cash Conversion Cycle | -3.21 | 5.26 | -0.32 | 11.91 | 15.03 |
| Days of Sales Outstanding | 19.66 | 21.77 | 23.83 | 28.22 | 30.20 |
| Days of Inventory Outstanding | 16.86 | 27.36 | 20.98 | 19.04 | 19.32 |
| Days of Payables Outstanding | 39.73 | 43.87 | 45.13 | 35.36 | 34.48 |
| Operating Cycle | 36.52 | 49.13 | 44.81 | 47.26 | 49.52 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 286.16 | 115.80 | 257.89 | 268.07 | 76.41 |
| Free Cash Flow Per Share | 225.40 | 59.53 | 199.07 | 210.41 | 26.47 |
| Dividend Paid and CapEx Coverage Ratio | 3.84 | 1.52 | 3.64 | 3.74 | 1.19 |
| Capital Expenditure Coverage Ratio | 4.71 | 2.06 | 4.38 | 4.65 | 1.53 |
| Operating Cash Flow Coverage Ratio | 0.22 | 0.09 | 0.21 | 0.28 | 0.07 |
| Operating Cash Flow to Sales Ratio | 0.05 | 0.02 | 0.05 | 0.05 | 0.01 |
| Free Cash Flow Yield | 44.63% | 12.27% | 30.86% | 34.44% | 3.64% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 50.75 | -14.96 | -19.34 | 17.25 | 15.20 |
| Price-to-Sales (P/S) Ratio | 0.08 | 0.09 | 0.12 | 0.11 | 0.13 |
| Price-to-Book (P/B) Ratio | 0.85 | 0.80 | 0.92 | 0.83 | 1.03 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 2.24 | 8.15 | 3.24 | 2.90 | 27.50 |
| Price-to-Operating Cash Flow Ratio | 1.76 | 4.19 | 2.50 | 2.28 | 9.53 |
| Price-to-Earnings Growth (PEG) Ratio | -0.39 | 5.36 | 0.10 | -0.66 | 3.28 |
| Enterprise Value Multiple | 5.77 | 8.86 | 8.98 | 4.36 | 4.72 |
| Enterprise Value | 14.92B | 14.88B | 12.39B | 10.14B | 12.71B |
| EV to EBITDA | 5.77 | 8.86 | 8.98 | 4.36 | 4.72 |
| EV to Sales | 0.21 | 0.23 | 0.23 | 0.19 | 0.25 |
| EV to Free Cash Flow | 5.78 | 22.08 | 5.91 | 5.13 | 51.47 |
| EV to Operating Cash Flow | 4.55 | 11.35 | 4.56 | 4.02 | 17.83 |
| Tangible Book Value Per Share | -64.51 | -30.56 | 97.02 | 397.53 | 329.00 |
| Shareholders’ Equity Per Share | 597.28 | 606.72 | 699.35 | 731.98 | 708.04 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.85 | 48.75 | 3.39 | 0.67 | 0.65 |
| Revenue Per Share | 6068.17 | 5609.47 | 5175.40 | 5534.76 | 5530.61 |
| Net Income Per Share | 9.86 | -32.50 | -33.35 | 35.42 | 47.90 |
| Tax Burden | 0.16 | -46.00 | -2.45 | 0.32 | 0.34 |
| Interest Burden | 0.71 | 0.04 | 0.68 | 0.95 | 0.95 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.11 | 0.08 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 29.01 | -3.56 | -7.73 | 2.40 | 0.54 |
Currency in JPY
